Trials / Recruiting
RecruitingNCT06209580
AMT-253 in Patients With Advanced Solid Tumours
Phase I/II Study of AMT-253 in Patients With Unresectable or Metastatic Malignant Melanoma and Other Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- Multitude Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors. This study include phase I dose escalation and phase II dose expansion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMT-253 for injection | Administered intravenously |
Timeline
- Start date
- 2024-01-31
- Primary completion
- 2026-04-30
- Completion
- 2026-12-31
- First posted
- 2024-01-17
- Last updated
- 2025-09-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06209580. Inclusion in this directory is not an endorsement.